Compare Gilead Sciences, Inc. (GILD) vs Union Pacific Corporation (UNP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Union Pacific Corporation — how do they compare? Gilead Sciences, Inc. trades at $134.92 (market cap $163.51B), while Union Pacific Corporation trades at $298.71 (market cap $171.20B). The key difference: Gilead Sciences, Inc. and Union Pacific Corporation are close in size by market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | UNP | |
|---|---|---|
Market Cap | $163.51B | $171.20B |
Sector | Health | Industrials |
52-Week High | $155.80 | $289.13 |
52-Week Low | $108.22 | $214.91 |
Enterprise Value | $178.05B | $201.67B |
Dividend Yield | 2.49% | 1.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Union Pacific (UNP) trades at $297.49, up 3.19% today, showing strong momentum with a bullish technical outlook. The company maintains robust fundamentals with a 29.2% net income margin and 40.69% ROE, supported by consistent earnings beats. Recent news highlights the proposed merger with Norfolk Southern, which could drive long-term value despite regulatory scrutiny. Cash flow remains positive at $252 million for 2025, though 2026 projections indicate a potential decline.
Outlook is positive with a consensus price target of $311.07, suggesting 4.6% upside. Key opportunities include operational efficiency and merger synergies, while risks involve regulatory hurdles and a class-action lawsuit. The stock's current valuation at 23.73 P/E appears reasonable given growth prospects, but investors should monitor merger progress and quarterly earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →
